Curium lists Bexlutry at $63,524 per infusion, roughly 5% cheaper than Novartis' Lutathera

Curium announced the list price for its radioligand Bexlutry, a generic version of Novartis' Lutathera.

The price is set at $63,524 per infusion, which represents about a five percent discount compared with the cost of Lutathera.

This pricing move positions Curium as a lower-cost alternative in the competitive market for radioligand therapies.